Immunomodulatory cells and uses thereof
AssigneeSinai Health System
InventorsAndras Nagy, Jeffrey Harding, Kristina Nagy
Life of this patent
Estimating the term…
Abstract
Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.
Claims17
A eukaryotic cell genetically modified to comprise i) a set of transgenes comprising the following genes:
- PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASLG or FasL, Ccl21 or Ccl21b, Mfge8, and Serpin B9 or Spi6;
- and ii) a transgene encoding a polypeptide comprising a self-antigen associated with an autoimmune disease.
Dependencies are inferred from the claim text.